Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 18, 2018JAMA Cardiology

Left ventricular assist device therapy for advanced heart failure has evolved significantly, with mean survival following implantation now reaching nearly 5 years.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with advanced or end-stage heart failure

Design

Review

Key result

Left ventricular assist device therapy for advanced heart failure has evolved significantly, with mean survival following implantation now reaching nearly 5 years.

Authors

LMLeslie W. MillerJRJoseph G. Rogers

Discussion

Loading...

Member takes

Overview

Enhances survival outlook for advanced HF; leaves open strategies to reduce persistent complications.

Structured PICO

P
Population
Patients with advanced or end-stage heart failure
I
Intervention
Left ventricular assist devices (LVADs)

LVAD therapy has evolved significantly, providing nearly 5 years of mean survival for advanced heart failure patients, though complications remain a limitation.

Cite This Study

Miller et al. (2018) conducted a review in Advanced heart failure. Left ventricular assist devices was evaluated. Left ventricular assist device therapy for advanced heart failure has evolved significantly, with mean survival following implantation now reaching nearly 5 years.

synapsesocial.com/papers/6a12407841f2b0889a38cfffhttps://doi.org/10.1001/jamacardio.2018.0522
View Full Paper
Ask AI
Bookmark
Share